跳至主要内容
临床试验/NCT02239822
NCT02239822已完成2 期

Double Blinded Randomized Trial of eTNS as Adjuvant Treatment for Major Unipolar Depressive Disorder.

Hospital do Coracao2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年12月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
50
试验地点
2
主要终点
Identify a efficacy of eTNS of the V1 branch of the trigeminal nerve

研究概览

简要总结

Double Blinded Randomized Trial of eTNS as adjuvant treatment for Major Unipolar Depressive Disorder. The primary objective is to assess the safety and tolerability of eTNS (external trigeminal nerve stimulation) of the V1 branch of the trigeminal nerve as an adjunctive treatment for adult patients with the diagnosis of unipolar MDD (Major Depressive Disorder).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients with non-psychotic, unipolar Major Depressive Disorder assessed via the MINI structured interview and legally capacitated to sign the informed consent for participation in the study;
  • A score of ≥ 14 on the HAM-D17 with Item 1 (depressed mood) ≥ 2;
  • A history of treatment failure with at least 3 adequate trials antidepressants over the previous 6 weeks and less than 6 medications, with no change in antidepressant medication or dose within the previous 6 weeks, and ongoing use of at least one antidepressant (which will continue during participation in the study);
  • Patients with suicidal ideation are eligible only if the thoughts of death or of life not being worth living are not accompanied by a plan or intention for self-harm and lack of self-harming attempt in the past 6 months;
  • Patients with appropriate support to be compliant with the study protocol.

排除标准

  • Patient is mentally or legally incapacitated, unable to give informed consent;
  • Patients with psychosis (psychotic depression, schizophrenia, or schizoaffective diagnoses (lifetime); bipolar disorder (lifetime); dementia (lifetime); delirium or any substance abuse disorder within the past 6 months; eating disorder within the past year; obsessive-compulsive disorder (lifetime); post-traumatic stress disorder within the past year; acute risk for suicide or self-injurious behavior. Patients with diagnostic uncertainty or ambiguity (e.g. rule-out pseudo-dementia of depression) will be excluded;
  • Patients currently receiving more than six medications for treatment of MDD;
  • Patients with exposure to ECT or rTMS or any investigational treatment (for any disorder) within the past 6 months;
  • Prior VNS and/or DBS therapy (lifetime);
  • Past history of skull fracture; cranial surgery entering the calvarium; space occupying intracranial lesion; stroke, CVA, or TIAs; cerebral aneurysm; Parkinson's or Huntington's disease; or Multiple Sclerosis.
  • Current pregnancy, breast feeding, plans to become pregnant during the study, or not using a medically accepted means of contraception;
  • Other medical conditions that would increase the risk of infection or surgical related morbidity and/or would affect compliance with the study protocol.

结局指标

主要结局

Identify a efficacy of eTNS of the V1 branch of the trigeminal nerve

时间窗: 48 weeks

We will use the Hamilton Rating Scale for Depression (HRSD) 17 scores as the main outcome measure to assess the efficacy of sTNS of the V1 branch of the trigeminal nerve as adjunctive treatment for MDD.

次要结局

  • Identify the tolerability of eTNS stimulation(48 weeks)
  • Identify the duration of the placebo effect(48 weeks)
  • Identify the long-term recurrence rate of eTNS therapy(48 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验